BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $582,067.42 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 25,687 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $582,067.42. Following the sale, the chief financial officer now directly owns 189,242 shares of the company’s stock, valued at $4,288,223.72. This represents a 11.95 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, March 11th, Troy Wichterman sold 4,151 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total value of $103,775.00.
• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total transaction of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Stock Down 5.6 %

BLFS traded down $1.34 during midday trading on Thursday, reaching $22.44. 591,144 shares of the company were exchanged, compared to its average volume of 358,590. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -21.17 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55. The company’s fifty day moving average price is $26.11 and its 200 day moving average price is $25.54.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter last year, the business posted ($0.21) EPS. As a group, analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on BLFS shares. KeyCorp upped their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Northland Securities boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. HC Wainwright raised their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Benchmark reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, StockNews.com lowered shares of BioLife Solutions from a “hold” rating to a “sell” rating in a report on Monday. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions has an average rating of “Moderate Buy” and an average target price of $29.86.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. increased its stake in shares of BioLife Solutions by 1.1% during the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider’s stock worth $84,097,000 after purchasing an additional 36,176 shares during the last quarter. Fred Alger Management LLC raised its stake in BioLife Solutions by 1.0% in the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider’s stock valued at $41,386,000 after acquiring an additional 16,274 shares during the period. State Street Corp boosted its position in BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares during the period. Millennium Management LLC increased its stake in shares of BioLife Solutions by 49.1% in the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after purchasing an additional 377,111 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of BioLife Solutions by 4.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider’s stock worth $23,028,000 after purchasing an additional 40,416 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.